Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehaf585 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Data on the levels of rivaroxaban-specific anti-factor Xa activity (AFXaA) within three weeks of starting high-dose rivaroxaban therapy in patients with cancer-associated thromboembolism (CAT) is limited. This study aimed to determine initial levels of rivaroxaban-specific AFXaA in patients with CAT to assist with drug monitoring.
Methods: This study included a total of 33 patients from December 2017 through January 2019.
Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials.
Res Pract Thromb Haemost
July 2025
Division of Cardiology, Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, California, USA.
Background: Venous thromboembolism (VTE) is a major cause of cardiovascular morbidity and mortality globally. Although direct oral anticoagulants (DOACs) have improved extended VTE treatment, the optimal dose for balancing efficacy and safety remains unclear.
Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of reduced-dose DOACs vs full-dose regimens during extended anticoagulation for VTE.
Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: a prospective cohort study.
J Thromb Haemost
September 2025
Department of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Background: Recurrent venous thromboembolism (VTE) is a common complication in patients with cancer-associated VTE. Limited data are available on treatment, particularly in patients receiving direct oral anticoagulants (DOACs). We aimed to evaluate current management strategies and outcomes in patients with cancer and recurrent VTE during treatment with low-molecular-weight heparin (LMWH) or DOACs.
View Article and Find Full Text PDFA 10-year review of iliofemoral deep vein thrombosis - are they more dangerous than their distal counterparts?
J Thromb Thrombolysis
September 2025
Department of Haematology, Northern Hospital, 185 Cooper St, Epping, VIC, 3076, Australia.
Iliofemoral deep vein thrombosis (IFDVT) is associated with potential for poor outcomes despite optimal anticoagulation therapy. To characterize the real-world management of IFDVT in an Australian population. Retrospective evaluation of IFDVT cases managed at Northern Health, Australia from January 2011 to December 2020 was performed and compared to non-iliofemoral lower limb DVTs (non-IFDVT) (n = 1793).
View Article and Find Full Text PDFEfficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.
Clin Appl Thromb Hemost
September 2025
The Maldives National University, Rahdhebai Hingun, Malé.
BackgroundCancer patients are at significantly increased risk of venous thromboembolism (VTE), a leading cause of morbidity and mortality in this population. While traditional anticoagulants like low-molecular-weight heparin (LMWH) and vitamin K antagonists (VKAs) are commonly used, their limitations have prompted growing interest in direct oral anticoagulants (DOACs), particularly Factor Xa inhibitors. However, concerns about bleeding risks persist.
View Article and Find Full Text PDF